小鼠锁骨上棕色脂肪组织的解剖、组织学处理及基因表达分析
2024年3月29日
3.3K 次观看
在这里，我们提供了一个实用的程序，用于解剖和执行小鼠锁骨上棕色脂肪组织的组织学和基因表达分析。
1 我们的实验室专注于建立2 锁骨上棕色脂肪组织 3 或 SCBAT 作为棕色脂肪分析的有价值的仓库 4，因为它的解剖学相似性 5 与人类棕色脂肪组织相似。6 该协议旨在提高SCBAT 研究的可及性 7。8 这个仓库可能令人生畏，因为它的尺寸小 9 并且靠近颈部的大静脉， 10 因此，必须提供 11 一种提取和处理 SCBAT 的简单方法。
12 我们的方法脱颖而出13 首先是在提取 SCBAT 时使用解剖显微镜 14。15 这提高了精度 16 和提取效率，17 这在使用如此小的组织仓库时都至关重要 18。19 其次，我们在进行基因表达分析 21 之前对冷冻的 SCBAT 样品 20 进行了匀浆，以提高 RNA 产量，以补偿 22 如此少量的可用组织。
23 我们目前专注于定义24 SCBAT 的遗传衬里边缘，25 确定调节其发育的变形网络 26,27 并开发一个大脑模型 28 来探索它在人类中的生理功能。
概述
本研究提供了从小鼠解剖锁骨上棕色脂肪组织（scBAT）的详细方案，由于其与人类棕色脂肪组织的解剖相似性，这被认为是分析棕色脂肪的宝贵模型。重点是通过精确的解剖和随后的组织学及基因表达分析来改善对scBAT研究的可及性。
关键研究组成部分
研究领域
- 锁骨上棕色脂肪组织（scBAT）
- 基因表达分析
- 组织学技术
背景
- scBAT因其在代谢研究中的潜在重要性而受到认可。
- 与主要静脉的解剖接近性在解剖时带来了挑战。
- 已确认需要便捷和准确的提取方法。
使用的方法
- 使用显微镜进行解剖以确保精确。
- 组织均质化后的基因表达分析。
- 用于组织学评估的苏木精和伊红染色。
主要结果
- 所描述的方案提高了提取效率和基因表达数据的质量。
- scBAT显示了棕色脂肪组织中的特征组织结构。
- 该研究为理解scBAT的遗传谱系和生理角色奠定了基础。
结论
- 该方案使得对scBAT在代谢中的作用进行更有效的研究成为可能。
- 研究结果为脂肪组织生物学的更广泛领域做出了贡献。
常见问题
什么是锁骨上棕色脂肪组织（scBAT）？
scBAT是一种位于锁骨附近的特殊类型棕色脂肪，因其代谢功能而显著。
为什么scBAT对研究很重要？
由于其与人类棕色脂肪组织的解剖相似性，scBAT是研究代谢过程的极好模型。
在解剖scBAT时存在哪些挑战？
其小尺寸和靠近主要静脉的位置可能使解剖过程复杂化。
该方案如何提高提取效率？
它使用解剖显微镜以提高精确度，并利用组织均质化来改善RNA产量。
研究中使用的主要技术是什么？
研究使用解剖、组织学染色和基因表达分析技术。
关于scBAT的细胞结构的主要发现是什么？
苏木精和伊红染色确认了scBAT样本中典型棕色脂肪组织特征的存在。
这项研究建议哪些未来的研究方向？
该研究建议确定scBAT的遗传谱系和生理功能，以及开发离体模型以进行进一步研究。
Executive Industry Relevance
Precise dissection and molecular analysis of murine supraclavicular brown adipose tissue (scBAT) enable translational insights into human metabolic regulation. This protocol advances early discovery by providing access to a depot anatomically analogous to human BAT, supporting mechanistic de-risking and target validation in metabolic disease research. Enhanced extraction and gene expression workflows improve predictive confidence for downstream portfolio decisions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of brown adipose tissue biology in a depot relevant to human physiology.
- Supports functional target validation by facilitating gene expression and morphological analyses.
- Improves mechanistic de-risking through precise tissue isolation and molecular characterization.
- Provides a platform for clarifying regulatory networks and developmental pathways in BAT.
Screening & Assay Development
- Delivers standardized tissue preparation for reproducible gene expression and histological assays.
- Optimizes sample homogenization to maximize RNA yield from small tissue depots.
- Facilitates quantitative assessment of marker gene expression for assay development.
- Enables reliable comparison between scBAT and other BAT depots for compound evaluation.
Translational & Preclinical Research
- Aligns murine scBAT studies with human BAT biology for translational biomarker exploration.
- Supports continuity from discovery through preclinical validation in metabolic disease models.
- Provides a foundation for ex-vivo modeling of BAT function relevant to human physiology.
- Enables risk-adjusted advancement of metabolic targets based on depot-specific data.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum by enabling precise hypothesis testing and molecular profiling of a disease-relevant BAT depot.
- Discovery Biology: Supports pathway clarification and biological de-risking through targeted gene expression analysis.
- Screening: Provides reproducible, quantitative outputs for assay readiness and cross-depot comparisons.
- Analytics: Delivers robust molecular and histological readouts to inform condition-specific analyses.
- Translational Research: Bridges murine and human BAT studies for biomarker alignment and preclinical continuity.
- Enterprise Reuse: Establishes a reusable workflow for scBAT extraction and analysis across metabolic research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in BAT research.
- Operational Value: Standardizes tissue processing and molecular analysis for reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio progression in metabolic disease pipelines.
- Portfolio Impact: Supports risk-adjusted prioritization of targets and models based on depot-specific data.
Implementation Considerations
- Requires expertise in murine dissection and molecular biology techniques.
- Needs access to dissecting microscopes, histology, and qPCR infrastructure.
- Demands cross-team standardization for tissue handling and data interpretation.
- May require adaptation for different mouse ages or genetic backgrounds.
- Limited by the small size and anatomical complexity of scBAT, necessitating precise technique.
Biopharma FAQs
Why does null hypothesis testing matter for scBAT gene expression?
Null hypothesis testing in scBAT gene expression analysis enables objective evaluation of whether observed differences in marker gene levels are statistically significant, supporting robust target validation. This ensures that any functional claims about scBAT are grounded in quantitative evidence. Such rigor is essential for advancing metabolic targets with confidence in early discovery.
How does independent variable isolation improve scBAT dissection workflows?
Isolating variables such as tissue depot, age, and processing conditions during scBAT dissection allows for controlled comparisons and reduces confounding factors. This precision enhances the reliability of downstream gene expression and histological analyses. It supports reproducible discovery and screening workflows across research teams.
What do quantitative dependent variable measurements enable in scBAT analysis?
Quantitative measurements of gene expression and histological features in scBAT provide actionable data for comparing depot function and molecular profiles. These outputs enable benchmarking against other BAT depots and inform assay development. They are critical for establishing predictive confidence in translational research.
Why are replication requirements critical for cross-functional scBAT studies?
Replication ensures that scBAT dissection and analysis protocols yield consistent results across operators and experiments. This reproducibility is vital for cross-functional collaboration, enabling data integration and comparison within and between research teams. It underpins enterprise-wide confidence in biological findings.
What statistical analysis capabilities are needed before implementing scBAT protocols?
Robust statistical analysis tools are required to assess gene expression differences, validate histological findings, and control for sample variability in scBAT studies. These capabilities support data-driven decision-making and reduce the risk of false positives in target validation. They are essential for advancing scBAT research within biopharma pipelines.
![使用[18F]FDG微PET / MR成像对小鼠中的棕色和米色脂肪组织进行可视化和定量](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62460.jpg%3Fv%3D2026-07-08T02%253A25%253A48.878Z&w=384&q=75)
